Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Morgan E, Soerjomataram I, Rumgay H, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: new Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163(3):649–658 e642. doi:10.1053/j.gastro.2022.05.054
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (Concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3
   PubMed Web of Science ®Google Scholar
• Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–1505. doi:10.1016/S1470-2045(19)30456-5
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. doi:10.1016/j.canlet.2017.04.024
   PubMed Web of Science ®Google Scholar
• Yap DWT, Leone AG, Wong NZH, et al. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: a Meta-analysis Including Low PD-L1 Subgroups. JAMA Oncol. 2023;9(2):215–224. doi:10.1001/jamaoncol.2022.5816
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang L, Wang D, et al. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma. Ther Adv Med Oncol. 2023;15:17588359231169981. doi:10.1177/17588359231169981
   Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, Phase 3 study. Lancet. 2021;398(10302):759–771. doi:10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386(5):449–462. doi:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: the ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326(10):916–925. doi:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (Jupiter-06): a multi-center phase 3 trial. Cancer Cell. 2022;40(3):277–288 e273. doi:10.1016/j.ccell.2022.02.007
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377. doi:10.1136/bmj-2021-068714
   Google Scholar
• Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29(2):473–482. doi:10.1038/s41591-022-02179-2
   PubMed Web of Science ®Google Scholar
• Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483–495. doi:10.1016/S1470-2045(23)00108-0
   PubMed Web of Science ®Google Scholar
• Chen K, Wang X, Yang L, Chen Z. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: a Systematic Review and Meta-Analysis and Literature Review. Cancer Control. 2021;28:1073274821997430. doi:10.1177/1073274821997430
   Web of Science ®Google Scholar
• Li Y, Ji Y, Shen L, et al. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma. Front Oncol. 2022;12:1015302. doi:10.3389/fonc.2022.1015302
   PubMed Web of Science ®Google Scholar
• Yao W, Zhao X, Gong Y, et al. Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer. ESMO Open. 2021;6(2):100094. doi:10.1016/j.esmoop.2021.100094
   PubMed Web of Science ®Google Scholar
• Zhu C, Shi Y, Li Q, et al. Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect. J Control Release. 2022;341:769–781. doi:10.1016/j.jconrel.2021.12.022
   PubMed Web of Science ®Google Scholar
• Xing W, Zhao L, Zheng Y, et al. The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer—A phase II study. Front Immunol. 2021;12:772450. doi:10.3389/fimmu.2021.772450
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Med. 2019;25(6):920–928. doi:10.1038/s41591-019-0432-4
   PubMed Web of Science ®Google Scholar
• Chen Z, Huang Y, Hu Z, et al. Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. Oncogenesis. 2021;10(10):71. doi:10.1038/s41389-021-00359-2
   PubMed Web of Science ®Google Scholar
• Xu J, Li Y, Fan Q, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label Phase 2 study (ORIENT-2). Nat Commun. 2022;13(1):857. doi:10.1038/s41467-022-28408-3
   PubMed Web of Science ®Google Scholar
• Satapathy S, Bhattacharya A, Sood A, et al. Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (177Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors. Cancer Biother. Radiopharm. 2022;37(1):23–29. doi:10.1089/cbr.2021.0053
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Z, Lu WL, Zhao GF. Study on the prognostic influencing factors of esophageal squamous cell carcinoma and the predictive value of inflammatory reaction indexes on its postoperative recurrence. Zhonghua Zhong Liu Za Zhi. 2023;45(2):160–164. doi:10.3760/cma.j.cn112152-20210326-00268
   PubMedGoogle Scholar
• Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, et al. Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021;11(6):1353–1367. doi:10.1158/2159-8290.CD-20-1312
   PubMed Web of Science ®Google Scholar
• Zhao J, Hu W, Zhang X, et al. Camrelizumab in combination with fluorouracil or taxol plus platinum chemotherapy as first-line treatment of esophageal squamous cell carcinoma: a multicenter, open-label, prospective cohort study. J Clin Oncol. 2022;40(16_suppl):e16084–e16084. doi:10.1200/JCO.2022.40.16_suppl.e16084
   Web of Science ®Google Scholar
• Zhao L, Xing W, Yang Y, et al. The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: a phase II study. J Clin Oncol. 2021;39(15_suppl):4051. doi:10.1200/JCO.2021.39.15_suppl.4051
   Google Scholar
• Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Cancer Sci. 2017;108(10):1974–1984. doi:10.1111/cas.13337
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Journal for Immunotherapy of Cancer. 2018;6:1–7. doi:10.1186/s40425-018-0383-1
   PubMed Web of Science ®Google Scholar
• Petrova MP, Eneva MI, Arabadjiev JI, et al. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer. Biosci Trends. 2020;14(1):48–55. doi:10.5582/bst.2019.01279
   PubMed Web of Science ®Google Scholar
• Banna G, Di Quattro R, Malatino L, et al. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clin Transl Oncol. 2020;22:2130–2135. doi:10.1007/s12094-020-02337-3
   PubMed Web of Science ®Google Scholar
• Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Can Cell Inter. 2021;21(1):356. doi:10.1186/s12935-021-02072-x
   PubMed Web of Science ®Google Scholar
• Russo A, Russano M, Franchina T, et al. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a Large Retrospective Multicenter Study. Adv Ther. 2020;37(3):1145–1155. doi:10.1007/s12325-020-01229-w
   PubMed Web of Science ®Google Scholar
• Zeng R, Liu F, Fang C, et al. PIV and PILE score at baseline predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients. Front Immunol. 2021;12:724443. doi:10.3389/fimmu.2021.724443
   PubMed Web of Science ®Google Scholar
• Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1–13. doi:10.1016/j.ctrv.2017.05.005
   PubMed Web of Science ®Google Scholar
• Qi Y, Liao D, Fu X, Gao Q, Zhang Y. Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. Int Immunopharmacol. 2019;74:105707. doi:10.1016/j.intimp.2019.105707
   PubMed Web of Science ®Google Scholar
• Fan X, Wang D, Zhang W, et al. Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy. Front Cell Dev Biol. 2021;9:638312. doi:10.3389/fcell.2021.638312
   PubMed Web of Science ®Google Scholar
• Lin S, Peng T, Meng Y, et al. Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis. Aging (Albany NY). 2022;14(4):1959–1982. doi:10.18632/aging.203919
   PubMedGoogle Scholar
• Belani CP, Dakhil S, Waterhouse DM, et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol. 2007;18(1):110–115. doi:10.1093/annonc/mdl344
   PubMed Web of Science ®Google Scholar